0 false false false true false false false true false false true false false false false false false No description of principal activity 2022-03-01 Sage Accounts Production Advanced 2021 - FRS102_2021 144 xbrli:pure xbrli:shares iso4217:GBP 13343595 2022-03-01 2023-02-28 13343595 2023-02-28 13343595 bus:RegisteredOffice 2022-03-01 2023-02-28 13343595 bus:LeadAgentIfApplicable 2022-03-01 2023-02-28 13343595 bus:Director1 2022-03-01 2023-02-28 13343595 core:WithinOneYear 2023-02-28 13343595 core:ShareCapital 2023-02-28 13343595 core:RetainedEarningsAccumulatedLosses 2023-02-28 13343595 bus:SmallEntities 2022-03-01 2023-02-28 13343595 bus:AuditExemptWithAccountantsReport 2022-03-01 2023-02-28 13343595 bus:FullAccounts 2022-03-01 2023-02-28 13343595 bus:PrivateLimitedCompanyLtd 2022-03-01 2023-02-28
COMPANY REGISTRATION NUMBER: 13343595
Doctorpharma Ltd
Unaudited Financial Statements
28 February 2023
Doctorpharma Ltd
Financial Statements
Year ended 28 February 2023
Contents
Page
Officers and professional advisers
1
Strategic report
2
Director's report
3
Report to the director on the preparation of the unaudited statutory financial statements
4
Statement of comprehensive income
5
Statement of financial position
6
Notes to the financial statements
7
Doctorpharma Ltd
Officers and Professional Advisers
Director
Mr Z Jin
Registered office
71-75 Shelton Street
Covent Garden
London
United Kingdom
WC2H9JQ
Accountants
Sadler Talbot Ltd
Chartered accountants
5 Minton Place
Victoria Road
Bicester
Oxon
OX26 6QB
Doctorpharma Ltd
Strategic Report
Year ended 28 February 2023
This report was approved by the board of directors on 8 November 2023 and signed on behalf of the board by:
Mr Z Jin
Director
Registered office:
71-75 Shelton Street
Covent Garden
London
United Kingdom
WC2H9JQ
Doctorpharma Ltd
Director's Report
Year ended 28 February 2023
The director presents his report and the unaudited financial statements of the company for the year ended 28 February 2023 .
The company has been dormant as defined in section 1169 of the Companies Act 2006 throughout the year and preceding financial year. It is anticipated that the company will remain dormant for the foreseeable future.
Director
The director who served the company during the year was as follows:
Mr Z Jin
Dividends
The director does not recommend the payment of a dividend.
This report was approved by the board of directors on 8 November 2023 and signed on behalf of the board by:
Mr Z Jin
Director
Registered office:
71-75 Shelton Street
Covent Garden
London
United Kingdom
WC2H9JQ
Doctorpharma Ltd
Report to the Director on the Preparation of the Unaudited Statutory Financial Statements of Doctorpharma Ltd
Year ended 28 February 2023
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Doctorpharma Ltd for the year ended 28 February 2023, which comprise the statement of comprehensive income, statement of financial position and the related notes from the company's accounting records and from information and explanations you have given us. As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at www.accaglobal.com/en/member/professional-standards/rules-standards/acca-rulebook.html. This report is made solely to the director of Doctorpharma Ltd in accordance with the terms of our engagement letter dated ***Please fill in the Date of Engagement in field 9 of Client Database > Setup > Action Dates***. Our work has been undertaken solely to prepare for your approval the financial statements of Doctorpharma Ltd and state those matters that we have agreed to state to you in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at www.accaglobal.com/content/dam/ACCA_Global/Technical/fact/technical-factsheet-163.pdf. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Doctorpharma Ltd and its director for our work or for this report.
It is your duty to ensure that Doctorpharma Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Doctorpharma Ltd. You consider that Doctorpharma Ltd is exempt from the statutory audit requirement for the year. We have not been instructed to carry out an audit or a review of the financial statements of Doctorpharma Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
Sadler Talbot Ltd Chartered accountants
5 Minton Place Victoria Road Bicester Oxon OX26 6QB
8 November 2023
Doctorpharma Ltd
Statement of Comprehensive Income
Year ended 28 February 2023
2023
Note
£
Administrative expenses
144
----
Operating loss
( 144)
----
Loss before taxation
( 144)
Tax on loss
----
Loss for the financial year and total comprehensive income
( 144)
----
All the activities of the company are from continuing operations.
No significant accounting transactions as defined by section 1169 of the Companies Act 2006 occurred in the current year.
Doctorpharma Ltd
Statement of Financial Position
28 February 2023
2023
Note
£
£
Current assets
Debtors
4
10,000
Creditors: amounts falling due within one year
5
144
--------
Net current assets
9,856
-------
Total assets less current liabilities
9,856
-------
Net assets
9,856
-------
Capital and reserves
Called up share capital
6
10,000
Profit and loss account
( 144)
--------
Shareholders funds
9,856
--------
For the year ending 28 February 2023 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 8 November 2023 , and are signed on behalf of the board by:
Mr Z Jin
Director
Company registration number: 13343595
Doctorpharma Ltd
Notes to the Financial Statements
Year ended 28 February 2023
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 71-75 Shelton Street, Covent Garden, London, WC2H9JQ, United Kingdom.
2. Statement of compliance
These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Income statement
The company is dormant as defined by section 1169 of the Companies Act 2006. The company incurred no significant transactions during the current year or prior year.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Debtors
2023
£
Other debtors
10,000
--------
5. Creditors: amounts falling due within one year
2023
£
Accruals and deferred income
144
----
6. Called up share capital
Issued, called up and fully paid
2023
No.
£
7. Analysis of changes in net debt
At 1 Mar 2022
Cash flows
At 28 Feb 2023
£
£
£